rethinkTHC Search
Menu
Study breakdown

Cannabis Compound THCV Changes Brain Network Connectivity in Ways Relevant to Obesity

Randomized Controlled TrialPreliminary evidence
The takeaway

A single dose of THCV, a cannabis-derived CB1 neutral antagonist, reduced default mode network connectivity and increased executive control network connectivity in healthy volunteers, suggesting potential for obesity treatment.

Read this if you are interested in the neuroscience of appetite control and how different cannabinoids affect the brain.

THCV normalized an obesity-related brain connectivity pattern

What the researchers found

Researchers gave 20 healthy volunteers a single 10mg oral dose of THCV or placebo in a randomized crossover design, then scanned their brains with resting-state fMRI.

THCV produced no subjective effects (no feeling of being high), as expected for a CB1 neutral antagonist. However, it significantly altered brain network connectivity: reducing connections between the amygdala and the default mode network while increasing connections between the amygdala and the dorsal anterior cingulate cortex (part of the executive control network).

Under placebo, amygdala-precuneus connectivity correlated positively with body mass index. This correlation disappeared under THCV, suggesting the drug may normalize an obesity-related brain connectivity pattern.

Why it matters

The CB1 inverse agonist rimonabant was effective for obesity but caused depression. THCV is a neutral antagonist, meaning it blocks the receptor without the inverse agonist activity that may cause psychiatric side effects. This study suggests THCV affects brain networks relevant to obesity without mood changes.

The numbers in context

20 volunteers; 10mg oral THCV; no subjective effects; reduced default mode network connectivity; increased cognitive control network connectivity; BMI correlation with amygdala-precuneus connectivity eliminated under THCV

How the study worked

Randomized, within-subject, double-blind, placebo-controlled study. 20 healthy volunteers received 10mg oral THCV or placebo. Resting-state fMRI with seed-based connectivity analyses. Regions of interest: amygdala, insula, orbitofrontal cortex, dorsal medial prefrontal cortex.

What this study cannot tell us

Very small sample (n=20). Single dose only. Healthy volunteers, not obese individuals. No measurement of food intake or weight. Resting-state connectivity changes do not prove clinical efficacy.

How to read the evidence

Well-designed crossover RCT with objective neuroimaging, but small sample, single dose, and no clinical outcomes measured.

When this study was published

Published in 2015. THCV research for metabolic conditions has continued.

The bigger picture

THCV could potentially offer the weight-management benefits of CB1 blockade (like rimonabant) without the depression and anxiety that led to rimonabant's withdrawal. These early brain imaging findings support further investigation.

Questions still open

  • Would chronic THCV dosing produce sustained brain changes and weight loss? Does THCV truly avoid the psychiatric side effects of rimonabant? Would these connectivity changes be more pronounced in obese individuals?

Common questions

What is THCV?
Tetrahydrocannabivarin (THCV) is a naturally occurring cannabinoid in cannabis that acts as a neutral antagonist at CB1 receptors. Unlike THC, it does not produce a high. It has been investigated for appetite suppression and metabolic effects.
Could THCV help with weight loss?
This study showed THCV changes brain connectivity in ways associated with obesity, without causing mood changes. However, it was a small brain imaging study in healthy volunteers, not a weight loss trial. More research is needed.

Read the original research

The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.

The international journal of neuropsychopharmacology, 19(2)

Citation

Rzepa, Ewelina; Tudge, Luke; McCabe, Ciara. (2015). The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.. The international journal of neuropsychopharmacology, 19(2). https://doi.org/10.1093/ijnp/pyv092

Explore the wider topic